Rheumatoid Arthritis

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties.

RedHill completed a pre-clinical study designed to evaluate the therapeutic effects of RHB-104 using the Collagen-Induced Arthritis (CIA) pre-clinical model.

The results from the pre-clinical study demonstrated that disease severity was significantly reduced in the RHB-104 arm, indicating that RHB-104 was effective in treating CIA in the study.